4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Portico NG Approval Study

Portico NG Approval Study

Study Description
Brief Summary:
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Portico™ NG Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Condition or disease Intervention/treatment Phase
Symptomatic Severe Aortic Stenosis Device: Portico™ NG Valve and FlexNav™ Delivery System Not Applicable

Detailed Description:

The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study.

Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure.

Subjects participating in the clinical study will be followed for a total of 12 months with data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually at 2, 3, 4 and 5 years.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 189 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Devices under investigation in this clinical study include the Portico™ NG Valve (23mm, 25mm, 27mm and 29mm sizes), FlexNav™ Delivery System(s) (small and large) and Portico™ NG Loading System(s) (small and large), all of which are currently approved for investigational use only.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Actual Study Start Date : September 17, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : July 2026
Arms and Interventions
Arm Intervention/treatment
Experimental: Portico™ NG valve, FlexNav™ Delivery System
Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
Device: Portico™ NG Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Outcome Measures
Primary Outcome Measures :
  1. Primary safety endpoint is all-cause mortality [ Time Frame: at 30 days ]
  2. Primary effectiveness endpoint is moderate or greater paravalvular leak [ Time Frame: at 30 days ]

Secondary Outcome Measures :
  1. Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications [ Time Frame: at 30 days ]

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documented heart team agreement of high or extreme risk for surgical aortic valve replacement due to frailty or co-morbidities not captured by the STS score.
  • Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart Association) Functional Classification of II, III, or IV.
  • Subject has senile degenerative aortic valve stenosis with echo-derived criteria, defined as: aortic valve area (AVA) of ≤ 1.0 cm2 (or indexed EOA (effective orifice area) ≤ 0.6 cm2/m2) AND mean gradient ≥40 mmHg or peak jet velocity ≥ 4.0 m/s or doppler velocity index (DVI) ≤0.25. (Qualifying AVA baseline measurement must be within 90 days prior to informed consent).
  • Aortic annulus diameter of 19-27mm and ascending aorta diameter of 26-42 mm for the specified valve size listed in the IFU (Instructions For Use), as measured by CT (Computed Tomography) conducted within 12 months prior to informed consent. (If a CT is contraindicated and/or not possible to be obtained for certain subjects, a 3D echocardiogram and non-contrast CT of chest and abdomen/pelvis may be accepted).

Exclusion Criteria:

  • Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure.
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure.
  • Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count <50,000 cells/mm³). History of bleeding diathesis or coagulopathy
  • Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation
  • Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA).
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+).
  • Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT), severe (greater than or equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise.
  • Minimum access vessel diameter of <5.0mm for small FlexNav™ Delivery System and <5.5 mm for large FlexNav™ Delivery System
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Mira Tissari +32 470 47 0942 mira.tissari@abbott.com
Contact: Mary-Margaret Seale +1 612 513 0822 mary.seale@abbott.com

Locations
Show Show 22 study locations
Sponsors and Collaborators
Abbott Medical Devices
Tracking Information
First Submitted Date  ICMJE July 4, 2019
First Posted Date  ICMJE July 8, 2019
Last Update Posted Date March 12, 2021
Actual Study Start Date  ICMJE September 17, 2019
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 7, 2020)
  • Primary safety endpoint is all-cause mortality [ Time Frame: at 30 days ]
  • Primary effectiveness endpoint is moderate or greater paravalvular leak [ Time Frame: at 30 days ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 4, 2019)
  • Primary safety endpoint is all-cause mortality [ Time Frame: at 30 days ]
  • Primary effectiveness endpoint is freedom from moderate or greater paravalvular leak [ Time Frame: at 30 days ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 7, 2020)
Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications [ Time Frame: at 30 days ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 4, 2019)
Secondary endpoint is freedom from mild or greater paravalvular leak [ Time Frame: at 30 days ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Portico NG Approval Study
Official Title  ICMJE Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Brief Summary The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Portico™ NG Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.
Detailed Description

The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study.

Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure.

Subjects participating in the clinical study will be followed for a total of 12 months with data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually at 2, 3, 4 and 5 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Devices under investigation in this clinical study include the Portico™ NG Valve (23mm, 25mm, 27mm and 29mm sizes), FlexNav™ Delivery System(s) (small and large) and Portico™ NG Loading System(s) (small and large), all of which are currently approved for investigational use only.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Symptomatic Severe Aortic Stenosis
Intervention  ICMJE Device: Portico™ NG Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Study Arms  ICMJE Experimental: Portico™ NG valve, FlexNav™ Delivery System
Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
Intervention: Device: Portico™ NG Valve and FlexNav™ Delivery System
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 7, 2020)
189
Original Estimated Enrollment  ICMJE
 (submitted: July 4, 2019)
140
Estimated Study Completion Date  ICMJE July 2026
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documented heart team agreement of high or extreme risk for surgical aortic valve replacement due to frailty or co-morbidities not captured by the STS score.
  • Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart Association) Functional Classification of II, III, or IV.
  • Subject has senile degenerative aortic valve stenosis with echo-derived criteria, defined as: aortic valve area (AVA) of ≤ 1.0 cm2 (or indexed EOA (effective orifice area) ≤ 0.6 cm2/m2) AND mean gradient ≥40 mmHg or peak jet velocity ≥ 4.0 m/s or doppler velocity index (DVI) ≤0.25. (Qualifying AVA baseline measurement must be within 90 days prior to informed consent).
  • Aortic annulus diameter of 19-27mm and ascending aorta diameter of 26-42 mm for the specified valve size listed in the IFU (Instructions For Use), as measured by CT (Computed Tomography) conducted within 12 months prior to informed consent. (If a CT is contraindicated and/or not possible to be obtained for certain subjects, a 3D echocardiogram and non-contrast CT of chest and abdomen/pelvis may be accepted).

Exclusion Criteria:

  • Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure.
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure.
  • Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count <50,000 cells/mm³). History of bleeding diathesis or coagulopathy
  • Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation
  • Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA).
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+).
  • Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT), severe (greater than or equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise.
  • Minimum access vessel diameter of <5.0mm for small FlexNav™ Delivery System and <5.5 mm for large FlexNav™ Delivery System
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Mira Tissari +32 470 47 0942 mira.tissari@abbott.com
Contact: Mary-Margaret Seale +1 612 513 0822 mary.seale@abbott.com
Listed Location Countries  ICMJE Australia,   Denmark,   Italy,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04011722
Other Study ID Numbers  ICMJE ABT-CIP-10297
ABT-CIP-10308 ( Other Identifier: Abbott )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Abbott Medical Devices
Study Sponsor  ICMJE Abbott Medical Devices
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Abbott Medical Devices
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP